A new drug successfully attacks what was previously considered an undruggable mutation in pancreatic cancer nearly doubling patient survival rates.
Tag: Daraxonrasib
Pancreatic Cancer Drug Daraxonrasib Targets KRAS Mutation and Nearly Doubles Survival
Scientists developed a new drug that successfully targets the previously undruggable KRAS mutation which drives most pancreatic cancers nearly doubling patient survival in trials.
New Drug Daraxonrasib Cracks Undruggable Pancreatic Cancer Target and Nearly Doubles Survival
A new drug targeting the KRAS mutation driving most pancreatic cancers shows remarkable results in clinical trials nearly doubling patient survival time